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Abstract
Objective: To determine the frequency of detection of 
cytomegalovirus (CMV) among infants evaluated for late-
onset sepsis in the neonatal intensive care unit (NICU).
Methods: This study was a prospective cohort study.
Results: During the 13-month study, 84 infants under-
went 116 sepsis evaluations, and CMV DNA was detected 
in saliva in three (4%) infants (median: gestational age 
28 weeks, birth weight 950 g), representing 5% (n = 6) of 
all sepsis evaluations. One infant had CMV DNA detected 
in saliva in all four sepsis evaluations. Two infants had 
acquired CMV infection, while the timing of CMV acqui-
sition could not be determined in one infant. Two of the 
three infants had concomitant Gram-negative bacteremia 
and urinary tract infections (UTIs), two developed severe 
bronchopulmonary dysplasia (BPD) and none died.
Conclusion: Detection of CMV DNA in saliva occurred in 
4% of infants and 5% of sepsis evaluations. Persistence of 
CMV DNA shedding in saliva made attribution of clinical 
illness difficult to ascertain.
Keywords: acquired cytomegalovirus infection; cytomeg-
alovirus infection; neonatal sepsis.
Introduction
Postnatal detection of cytomegalovirus (CMV) among 
infants in the neonatal intensive care unit (NICU) has 
been associated with a sepsis-like syndrome as well as 
bronchopulmonary dysplasia (BPD), necrotizing enter-
ocolitis and even death [1–6]. Acquisition of CMV by 
infants in the NICU also results in asymptomatic infec-
tion and usually occurs by ingestion of unpasteurized 
human milk [7]. However, the incidence of CMV infec-
tion among infants in the NICU who are evaluated for 
possible late-onset sepsis is not known. Therefore, the 
objective of this study was to determine the frequency 
and potential impact of CMV detection among infants 
who were evaluated for late-onset sepsis in a Level 
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III NICU at Parkland Memorial Hospital (PMH), Dallas, 
TX, USA.
Materials and methods
Setting
This was a prospective cohort study of all infants who were hospitali-
zed in the NICU at PMH from January 15, 2012 to January 31, 2013 
and were enrolled in the viral respiratory infections in the neonatal 
intensive care unit (VIRIoN-I) study that determined the frequency 
and role of respiratory viral infections, as detected by polymerase 
chain reaction (PCR) testing, among infants who were evaluated 
for possible late-onset sepsis [8]. The PMH NICU is a 90-bed, Level 
IIIC, predominantly inborn unit with approximately 1400 admissions 
annually. The unit is staffed by neonatologists from the University 
of Texas Southwestern Medical Center, along with neonatology fel-
lows, neonatal nurse practitioners and pediatric residents. Infants 
with surgical conditions were cared for in the NICU pre- and post-
surgery. Infants who required extracorporeal membrane oxygenation 
or cardiac surgery other than patent ductus arteriosus ligation were 
transferred to Children’s Medical Center Dallas.
Mothers had unlimited access except in the high acuity area 
where visiting was discouraged from 9 AM to noon when daily 
patient rounds were held. While siblings ≥12 years of age could visit 
anytime with a parent, siblings <12 years of age only visited with a 
parent twice a week under the supervision of a child life specialist. 
Provision of either fresh or frozen maternal milk was encouraged, 
but there was no donor human milk used during the study period. 
In addition, there was no use of colostrum or human milk for oral 
hygiene. A leukoreduction transfusion policy was used during the 
study period and both CMV seropositive and seronegative red blood 
cell units were utilized after irradiation [9].
Patients
Infants were eligible if they were inborn, had never been discharged 
to home, were evaluated for possible late-onset sepsis and antibiotic 
therapy was initiated at >72 h of age. Evaluation for suspected sepsis 
was at the discretion of the attending neonatologist, as were deci-
sions regarding the use and duration of specific antimicrobial agents 
for all clinical scenarios. Eligible infants were identified by daily 
review of all antibiotics provided by the NICU pharmacists. Infants 
who received antibiotics for only superficial skin or surgical site 
infection were excluded.
After obtaining an informed consent from parents/guardians, 
the enrolled infants had saliva swabs obtained for CMV detection 
within 72 h of initiation of antibiotic therapy [8]. Their medical records 
were reviewed for pertinent maternal and infant demographic, clini-
cal, radiographic and laboratory data until discharge from the NICU. 
Congenital CMV infection was defined as detection of CMV from a 
clinical specimen before 21 days of age, while infants with acquired 
CMV infection had an initial negative CMV DNA PCR test but subse-
quently had CMV DNA detected in saliva after 21 days of age. Clini-
cal and laboratory definitions and abnormalities were determined 
as previously reported [8]. Briefly, hypothermia was defined as axil-
lary temperature <36 °C [10], while fever was temperature ≥38 °C [11]. 
Diagnosis of a urinary tract infection (UTI) was based on the neo-
natologist’s assessment in the medical record, bacterial growth on 
urine obtained by either suprapubic bladder aspiration (any growth 
of Gram-negative bacilli; >50,000 colony-forming units (CFU)/mL 
Gram-positive cocci) or catheterization (>50,000 CFU/mL) and/or 
receipt of ≥7  days of appropriate antibiotic therapy. Thrombocyto-
penia was <100,000/mm3 [12]. BPD was determined by the National 
Institutes of Health severity-based consensus definition [13]. The 
study was approved by the Institutional Review Board of the Univer-
sity of Texas Southwestern Medical Center.
Saliva specimens
Saliva swabs were stored at −80 °C, and subsequently processed 
for  CMV by quantitative PCR (Virology Laboratory, Nation-
wide  Children’s Hospital, Columbus, OH, USA) as previously 
described [14].
Statistical analyses
For descriptive statistics, normality of continuous covariates was 
assessed first using the Kolmogorov-Smirnov test. For normally dis-
tributed data, means with standard deviation (SD) were derived for 
descriptive statistics (e.g. patient demographics and characteristics), 
while median values with interquartile range (IQR) were calculated 
for non-normally distributed data. Proportions were calculated for 
categorical data. Bivariate analyses were performed to determine the 
association between the dependent variable (presence of virus) and 
independent covariates using t-tests for normally distributed data 
and the Mann-Whitney U-test for nonparametric data. Chi-square 
or Fisher’s exact tests were used for categorical variables as appro-
priate. A two-tailed P-value <0.05 was considered to be statistically 
significant. The Bonferroni correction was used to correct for mul-
tiple testing when groups that included multiple parameters were 
analyzed, with the corresponding P-values representing the adjusted 
values.
Results
During the 13-month study period, 84 (91%) of 92 eligible 
infants were enrolled (Figure 1). The mothers/legal guard-
ians of five infants declined enrollment in the study, while 
three infants were missed. The majority of mothers were 
Hispanic and delivered their infants by cesarean section 
(Table 1); four (4.7%) mothers were infected with the 
human immunodeficiency virus but the infants were unin-
fected. The infants were mostly male (51, 61%), preterm 
(81% <37  weeks’ gestation; 66% <34  weeks’ gestation) 
and of low birth weight (67% <2000 g birth weight; 57% 
<1500 g; 29% <1000 g; Table 1). The onset of clinical signs 
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of possible infection occurred at a median age of 18 days 
and the median duration of hospitalization was 65 days. 
The 84 infants received 116 evaluations for possible sepsis 
with initiation of antimicrobial therapy; 21 of them had 
two sepsis evaluations, eight had three and three had four 
performed. A saliva swab was collected at 112 (97%) sepsis 
evaluations.
Three (4%) of the 84 infants, representing six (5%) 
of the 116 sepsis evaluations, had CMV detected from the 
saliva swab (Figures 1 and 2; Tables 2 and 3). The clini-
cal signs that prompted the sepsis evaluation in these 
three infants included hypothermia (n = 4), fever (n = 2), 
tachypnea (n = 6) and apnea (n = 1). Two of the three 
infants (Patients #2, 3; Table 3, Figure 2) had negative 
saliva CMV PCR tests before 21  days of age (Patient #2, 
17 days of age; #3, 4 and 14 days of age; Table 3, Figure 2) 
before testing positive for CMV DNA at 85 and 27 days of 
age, respectively. Patient #2 was small for gestational age 
(SGA) and had received maternal milk before testing posi-
tive for CMV in saliva. Patient #3 did not receive mater-
nal milk but was transfused with packed red blood cells 
four times and platelets twice before testing positive for 
CMV DNA in saliva at 27 days of age. For clinical reasons 
unrelated to the study (thrombocytopenia), Patient #3 
also had a negative CMV urine culture 6 days before and 
8 and 25 days after testing positive for CMV DNA in saliva 
specimen. On the other hand, Patient #1 (Table 3, Figure 2) 
with gastroschisis was evaluated for sepsis four times and 
the saliva CMV DNA PCR test was positive in each evalua-
tion (37, 52, 100 and 120 days of age) with increasing CMV 
viral load from the first to the third evaluation. Patients 2 
and 3 developed severe BPD, while none were diagnosed 
with pneumonia, necrotizing enterocolitis or hearing loss. 
None of the infants received antiviral therapy, and all the 
three infants survived to NICU discharge.
Overall, the main reasons for the sepsis evaluations 
were respiratory signs (96%, 111/116), mainly tachypnea 
(89%, 103/116) and chest retractions (61%, 71/116), and 
gastrointestinal signs (47%, 54/116), principally feeding 
intolerance (39%, 45/116) and abdominal distension (28%, 
32/116) (Table 2). Compared to infants whose saliva CMV 
PCR test was negative, infants who had CMV detected in 
saliva swabs were older (37 vs. 15 days, P = 0.07) and had a 
lower platelet count (84,000/mL vs. 269,000/mL; P = 0.03) 
and a higher white blood cell count in the cerebrospinal 
fluid (247 cells/mL vs. 4 cells/mL, P = 0.015). None of the 
cerebrospinal fluids were tested for CMV by PCR or culture.
There was no difference in median duration of anti-
biotic therapy between CMV-positive and CMV-negative 
infants (3 days [IQR 2.7–9.2] vs. 5 days [IQR 2–7], respec-
tively; P = 0.84, Table 2). Two of the three infants who had 
CMV detected in saliva had blood and urine cultures posi-
tive for bacteria, with one having Klebsiella oxytoca bac-
teremia and Enterobacter cloacae UTI (urine obtained by 
bladder catheterization yielded 10,000 CFU/mL) while the 
92 Eligible infants:
- Inborn
- Never been discharged to home
- Evaluated for possible late-onset sepsis
- Antibiotic therapy initiated at >72 h of age 
84 (91%)
Infants enrolled
81 (96%) Infants:
CMV DNA not detected
in saliva
3 (4%) Infants:
CMV DNA detected in
saliva
116
Sepsis evaluations
6 (5%) Sepsis
evaluations:
CMV DNA detected in
saliva 
110 (95%) Sepsis
evaluations:
CMV DNA not detected
in saliva 
8 (9%) Infants excluded:
- 5 Refused consent
- 3 Not approached
Figure 1: Study population of inborn infants in the neonatal inten-
sive care unit who had saliva CMV DNA PCR testing performed when 
evaluated for possible late-onset sepsis with initiation of antibiotic 
therapy at >72 h of age.
Table 1: Characteristics of the 84 mothers and the enrolled infants.
No. of mothers   84
Age, year; mean ± SD, range   29 ± 7.5 (14–44)
Race/ethnicity
 Hispanic   68 (81%)
 Black   14 (17%)
 White   2 (2%)
Type of delivery
 Vaginal   27 (32%)
 Cesarean section   57 (68%)
No. of infants   84
Gestational age, week; median, IQR   29.5 (27–36)
Weight, g; median, IQR   1380 (900–2236)
Male gender   51 (60.7%)
Age at sepsis evaluation, days, median, IQR   18 (9–38)
Duration of hospitalization, days; median, IQR   65 (36–95)
SD, standard deviation; IQR, interquartile range.
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other infant had Escherichia coli isolated from the blood 
and urine (urine obtained by bladder catheterization 
yielded 100,000 CFU/mL; Tables 2 and 3. Figure 2). The 
third infant did not have any bacteria isolated from any of 
the sepsis evaluations, and none of the three infants had a 
respiratory virus detected in nasopharyngeal specimens. 
Infants in whom CMV was detected in saliva had a signifi-
cantly longer duration of hospitalization (117 ± 26  days) 
than infants without CMV detection (63 ± 38; P = 0.01; 
Table 2).
Discussion
This study represents the first time that the potential role 
of CMV in late-onset sepsis has been evaluated in a pro-
spective and systematic fashion. Among 84 infants in 
the NICU who underwent 116 sepsis evaluations with ini-
tiation of antibiotic therapy, three (4%) infants had CMV 
DNA detected in saliva by PCR testing in six (5%) sepsis 
evaluations. Overall, the three infants had 10 sepsis evalu-
ations performed with one infant having CMV detected in 
all four sepsis evaluations (Table 3, Figure 2). Although 
previous studies have associated postnatal CMV detection 
with a severe sepsis-like syndrome [6], necrotizing entero-
colitis [3, 4], BPD [1, 2] and mortality, the infants in this 
study mostly had temperature instability and respiratory 
signs. In addition, detection of CMV was associated with 
significantly lower platelet counts at the time of the sepsis 
evaluation (Table 2), and two infants developed severe 
BPD. While two infants also had a concomitant bacterial 
infection, namely bacteremia and UTI, none died.
This study highlights the problem of attributing 
clinical illness to detection of CMV in a clinical specimen 
among infants in the NICU. One of the infants had CMV 
A
DOL #37
Sepsis evaluation #1
CMV detected from saliva swab
Bacteremia (Klebsiella oxytoca)
UTI (Escherichia cloacae)
Respiratory viral PCR panel negative 
DOL #52
Sepsis evaluation #2
CMV detected from saliva swab
Bacterial cultures sterile
Respiratory viral PCR panel negative 
DOL #100
Sepsis evaluation #3
CMV detected from saliva swab
Bacterial cultures sterile
Respiratory viral PCR panel negative 
DOL#120
Sepsis evaluation #4
CMV detected from saliva swab
Bacterial cultures sterile
Respiratory viral PCR panel negative 
DOL #17
Sepsis evaluation #1
CMV not detected from saliva swab
Bacterial cultures sterile
Respiratory viral PCR panel negative
DOL #56
Sepsis evaluation #2
CMV not detected from saliva swab
Bacterial cultures sterile
Respiratory viral PCR panel negative
DOL #85
Sepsis evaluation #3
CMV detected from saliva swab
Escherichia coli bacteremia and UTI
Respiratory viral PCR panel negative 
DOL #4
Sepsis evaluation #1
CMV not detected from
saliva swab
Bacterial cultures sterile
DOL #14
Sepsis evaluation #2
CMV not detected from saliva swab
Bacterial cultures sterile
DOL #21
Evaluation for
thrombocytopenia
CMV not detected
from urine culture
DOL #27
Sepsis evaluation #3
CMV detected from saliva swab
Bacterial cultures sterile
DOL #35
Evaluation for
thrombocytopenia
CMV not detected from
urine culture
DOL #52
Evaluation for
thrombocytopenia
CMV not detected
from urine culture
B
C
Figure 2: Event timeline of the three infants who had CMV DNA detected in saliva by PCR testing.
(A) Patient #1 (Hispanic male; birth weight, 2760 g; gestational age, 36 weeks; gastroschisis; +maternal milk). (B) Patient #2 (Hispanic male; 
birth weight, 770 g; gestational age, 27 weeks; SGA; BPD; +maternal milk). (C) Patient #3 (Hispanic male; birth weight, 950 g; gestational 
age, 28 weeks; BPD; no maternal milk), CMV = Cytomegalovirus, PCR = polymerase chain reaction, g = grams, DOL = day of life, UTI = urinary 
tract infection, SGA = small for gestational age, BPD = bronchopulmonary dysplasia.
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Table 2: Characteristics of the 84 infants who had a sepsis evaluation performed at >72 h of age in the neonatal intensive care unit and had 
a saliva specimen obtained for detection of CMV DNA by polymerase chain reaction testing.
CMV detection in saliva
Yes No P-value
No. of infants 3 (4%) 81 (96%) –
 Gestational age, weeks; median, IQR 28 (28–32) 30 (27–36) 0.79
 Birth weight, g; median, IQR 950 (860–1855) 1380 (900–2223) 0.61
 Gender (male; n, %) 3 (100%) 48 (60%) 0.27
 Age at initial CMV detection/testing, days; median, IQR 37 (32–61) 15 (9–34) 0.07
 Weight at initial CMV detection/testing, g; median, IQR 2470 (1955–3018) 1658 (1079–2409) 0.18
No. of sepsis evaluations 6 (5%) 110 (95%)
 Temperature (T) instability
  Hypothermia (T < 36 °C) 0 21 (19%) 1.0
  Fever (T ≥ 38 °C) 2 (33%) 7 (6%) 0.14
 Apnea 1 (17%) 64 (58%) 0.08
 Respiratory signs
  Any 6 (100%) 105 (86%) 1.0
  Tachypnea 6 (100%) 97 (88%) 1.0
  Retractions 3 (50%) 68 (62%) 1.0
  Rhinorrhea 0 4 (3.6%) 1.0
  Congestion 0 2 (1.8%) 1.0
  Cough 0 3 (2.7%) 1.0
 Increased or need for oxygen 3 (50%) 79 (72%) 0.36
 Maximum respiratory support 2 (33%) 78 (71%) 0.7
  Nasal cannula 0 21 (19%) 1.0
  CPAP 1 (17%) 24 (22%) 1.0
  Mechanical ventilation 1 (17%) 33 (30%) 1.0
 Gastrointestinal signs
  Any 1 (17%) 53 (48%) 0.2
  Feeding intolerance 1 (17%) 44 (40%) 1.0
  Emesis 1 (17%) 26 (24%) 1.0
  Abdominal distension 1 (17%) 31 (28%) 1.0
 Hypotension 0 14 (13%) 1.0
  Fluid bolus (saline; intravenous) 0 14 (13%) 1.0
  Inotropic agents 0 8 (7%) 1.0
 Neurological signs:
  Any 1 (17%) 21 (19%) 1.0
  Lethargy 1 (17%) 13 (12%) 1.0
  Hypotonia 1 (17%) 9 (8%) 1.0
  Irritability 0 4 (4%) 1.0
 Hematological values (1st CMV detection)
  White cell blood count, cells/mL, median, IQR 7310 (6340–14340) 11,535 (8410–16425) 0.31
  Absolute total neutrophils, cells/mL, median, IQR 3140 (2830–8580) 4439 (3267–8120) 1.0
  Lymphocytes, cells/mL, median, IQR 3264 (2482–4290) 3845 (2626.7–5334) 1.0
  Platelets, #/mL, median, IQR 84,000 (34,000–224,000) 269,000 (172,000–387,000) 0.03
  Hemoglobin, g/dL, median, IQR 8 (8–11) 11 (9–13) 0.36
  Hematocrit, %, median, IQR 26 (26–35) 33 (28–39) 0.48
 Cerebrospinal fluid (n): 4 69
  Protein, mg/dL, median, IQR 246 (51–553) 132 (109–191) 0.83
  Glucose, mg/dL, median, IQR 48 (42–94) 53 (43–68) 0.88
  White blood cells, cells/mL, median, IQR 247 (28–1056) 4 (2–13) 0.015
 Bacterial co-infection
  Urine culture positive 2/6 (33%) 15/110 (14%) 0.21
  Blood culture positive 2/6 (33%) 20/110 (18%) 0.32
  CLABSI 1/6 (17%) 14/110 (13%) 0.57
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DNA detected at >21  days of age during all four sepsis 
evaluations and the contribution of CMV to each illness is 
questionable (Table 3, Figure 2). It is likely that this situa-
tion represented persistent CMV shedding that is known to 
occur for weeks to months after initial infection [15]. Inter-
estingly, this infant had Gram-negative bloodstream infec-
tion and UTI, and could represent reactivation of previous 
asymptomatic infection as in older individuals [16]. Two of 
the infants (Table 3, Figure 2; Patients 2, 3) had acquired 
CMV infection as both previously had negative saliva 
CMV PCR tests before 21 days of age. One of them (Table 3, 
Figure 2; Patient 3) had a low CMV saliva viral load at 
27 days of age, and had never received maternal milk but 
was transfused several times. This infant had urine CMV 
cultures performed as part of clinical care once before and 
twice after the saliva PCR test was positive, raising the 
possibility of a false-positive PCR test. However, CMV PCR 
has been shown to have higher sensitivity than culture [17, 
18], and it remains unknown how best to identify infants 
in the NICU with acquired CMV infection.
Limitations of this study include the relatively small 
sample size with the infrequent detection of CMV in the 
study patients, making associations difficult to assess. 
The low rate of CMV detection may be secondary to the 
enrollment of both term and preterm infants, as only 57% 
of the infants had a birth weight <1500 g and presumably 
at a higher risk of experiencing symptomatic postnatal 
CMV disease. In addition, the precise mode of acquisition 
of CMV in the three study infants could not be ascertained 
with certainty as the CMV serostatus of the mothers was 
unknown, detection of CMV in maternal milk was not 
performed and detection of CMV was not performed in 
the first 21 days of age to exclude congenital infection in 
one infant. Unfortunately, the frequency of maternal milk 
feeding in the study population was not known although 
the breast feeding rate among this predominantly His-
panic population was >90% (unpublished data). In addi-
tion, CMV testing was performed only if the infant was 
evaluated for sepsis and antibiotic therapy was initiated, 
so infants with milder clinical signs of possible infection 
were not identified [19]. Finally, blood CMV viral load was 
not performed, and this may be a better marker of acute 
and acquired infection. Nonetheless, how to attribute cau-
sation when CMV can be detected in multiple serial clini-
cal specimens remains problematic.
A strength of this study is its prospective nature with 
enrollment of 91% of all infants with clinical signs of 
possible sepsis. The infrequent detection of CMV during 
clinical sepsis episodes suggests that its role in causing 
acute infection is relatively low. In a meta-analysis of 
studies of human milk and acquired CMV infection in 
preterm, very-low-birth-weight infants, Lanzieri et  al. 
[20] reported that approximately 13–19% of infants fed 
fresh or frozen breast milk acquired CMV infection, but 
only 4–5% developed CMV-related sepsis-like illness 
[20–28].
In conclusion, detection of CMV DNA in saliva 
occurred in 4% of infants and 5% of sepsis evaluations, 
suggesting that CMV is not a major contributor to late-
onset sepsis in the NICU. The detection of CMV in clinical 
specimens is further complicated by its persistent shed-
ding in infected infants, making attribution of disease dif-
ficult at best. Only through universal screening of all NICU 
admissions and development of improved biomarkers of 
disease causation [29] will the true impact of this infection 
in the NICU setting be fully understood.
CMV detection in saliva
Yes No P-value
Respiratory viral infection 0 8/110 (7%)a 1
Antibiotic duration, days; median, IQR 3 (3–9) 5 (2–7) 0.84
Hearing loss at discharge 0 1/75 (1%) 1
Bronchopulmonary dysplasia
 Any 2 (67%) 21 (26%) 0.12
  Mild 0 10 (48%) 1.0
  Moderate 0 1 (5%) 1.0
  Severe 2 (100%) 13 (62%) 1.0
Duration of hospitalization, days, mean, SD 117 (±26) 63 (±38) 0.01
Death 0 4 (4%) 1
IQR, interquartile range; CMV, cytomegalovirus; CPAP, continuous positive airway pressure; SD, standard deviation; CLABSI, central 
line-associated bloodstream infection. aEnterovirus/rhinovirus, 2; rhinovirus, 2; coronaviruses, 2; parainfluenza-3 virus, 2. In bold 
P-value < 0.05.
Table 2 (continued)
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